Prime Medicine (PRME) Stock Overview
A biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
PRME Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Prime Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.01 |
| 52 Week High | US$6.94 |
| 52 Week Low | US$1.11 |
| Beta | 2.58 |
| 1 Month Change | 12.32% |
| 3 Month Change | -4.30% |
| 1 Year Change | 92.79% |
| 3 Year Change | -71.72% |
| 5 Year Change | n/a |
| Change since IPO | -73.91% |
Recent News & Updates
Recent updates
Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond
Dec 31Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359
Apr 25Prime Medicine: Gene Editing Company, Risky Investment
Feb 05Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Dec 19
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies
Nov 26Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns
Sep 04Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation
Sep 04Prime Medicine Stock: Only For The Most Patient Of Investors
Jun 20Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
May 14Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing
Jan 28Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Aug 25We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate
May 12Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?
Jan 24Shareholder Returns
| PRME | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.9% | -3.9% | -2.2% |
| 1Y | 92.8% | 22.8% | 16.9% |
Return vs Industry: PRME exceeded the US Biotechs industry which returned 22.8% over the past year.
Return vs Market: PRME exceeded the US Market which returned 16.9% over the past year.
Price Volatility
| PRME volatility | |
|---|---|
| PRME Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PRME's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PRME's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 146 | Allan Reine | primemedicine.com |
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs.
Prime Medicine, Inc. Fundamentals Summary
| PRME fundamental statistics | |
|---|---|
| Market cap | US$710.09m |
| Earnings (TTM) | -US$201.14m |
| Revenue (TTM) | US$4.63m |
Is PRME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRME income statement (TTM) | |
|---|---|
| Revenue | US$4.63m |
| Cost of Revenue | US$160.64m |
| Gross Profit | -US$156.00m |
| Other Expenses | US$45.14m |
| Earnings | -US$201.14m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | -3,367.96% |
| Net Profit Margin | -4,342.44% |
| Debt/Equity Ratio | 0% |
How did PRME perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 22:02 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prime Medicine, Inc. is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Samantha Lynn Semenkow | Citigroup Inc |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |